Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus
Open Access
- 1 April 2015
- journal article
- research article
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 29 (3) , 438-444
Abstract
No abstract availableKeywords
Funding Information
- Janssen Research & Development, LLC
This publication has 29 references indexed in Scilit:
- Standards of Medical Care in Diabetes—2014Diabetes Care, 2013
- Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitorsEndocrine, 2013
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialThe Lancet, 2013
- Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes MellitusThe Journal of Clinical Pharmacology, 2013
- Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized TrialHospital Practice, 2013
- Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulinDiabetes, Obesity and Metabolism, 2012
- Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Diabetologia, 2010
- Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary careDiabetic Medicine, 2007
- Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering EfficacyDiabetes Care, 2006
- Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added to Metformin Among Patients With Type 2 DiabetesDiabetes Care, 2005